| HOME >> MEDICINE >> TECHNOLOGY |
NEW YORK, July 2, 2012 /PRNewswire/ --
Carl Icahn today issued the following letter to Howard Solomon, Chairman, CEO and President of Forest Laboratories, Inc.:
CARL C. ICAHN
767 Fifth Avenue, 47th Floor
New York, NY 10153
July 2, 2012
Via Email and Federal Express
Howard Solomon
Chairman, CEO and President
Forest Laboratories, Inc.
909 Third Avenue
New York, NY 10022
Your recent statement is rife with inconsistencies, misstatements and doublespeak. I find your statement that we are attempting to distort and distract particularly disingenuous. You and I obviously have a vastly different definition of distortion and distraction. It seems to me that you would believe it to be a distraction if a member of the board would dare question the propriety of your receiving in excess of $60 million in compensation while you oversaw a 50% decline in the company's share price. Or perhaps you think it is a distraction if a member of the board asks whether it is appropriate to continue to keep stockholders in the dark regarding the succession plans of a company that has an 84-year old Chairman who has been the CEO for 35 years and has continually promoted his son (whose only other experience involves producing movies). It can never be a distraction and in fact it is the core role of the board to place the best interest of the shareholders over the interests of its Chairman and CEO and my greatest concern is that given the history and composition of this Board, this is not the case at Forest Labs.
Additionally, based on our "activist record", I find your statement that having our candidates on the Board would be a distraction both laughable and indefensible. We have greatly enhanced value in numerous companies on which we had minority board representation, particularly in bio-tech companies, which include Amylin, Biogen, Genzyme and Imclone. When our rep
'/>"/>SOURCE Carl Icahn
Copyright©2012 PR Newswire.
All rights reserved
Related medicine technology :
1. Icahn Issues Statement Regarding Amylin Pharmaceuticals
2. Patient Advocate Foundation Announces New Co-Pay Relief (CPR) Offerings for Patients Facing Health Issues Due to Electrolyte Imbalance
3. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
4. Upcoming Presentations on Global Market Access Issues and Trends in Health Economics and Outcomes Research at ISPOR 2012 by Novel Health Strategies
5. BD Issues 2011 Sustainability Report
6. Ameritox Announces Educational Resources to Help Physicians Navigate Complex Compliance Issues
7. OncoSec Medical Issues Letter to Shareholders
8. FDA Issues Complete Response Letter for 800mg PREZISTA® (darunavir) Tablet
9. PAREXEL International Issues Earnings Guidance In Conjunction With Investor Day
10. MLB All-Star Pitcher CC Sabathia Issues Fast Relief Challenge to Generate Donations for the American Red Cross
11. Alexza Receives Complete Response Letter for Adasuve™ NDA